Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL-004 is a preclinical-stage microbial therapy being developed by Bloom Science for the treatment of amino acid disorders. The drug's mechanism of action involves the biochemical conversion of toxic amino acids into non-toxic metabolites, likely mediated by engineered or specific strains of bacteria within the gut microbiome. By degrading harmful amino acids before they can accumulate systemically, BL-004 aims to provide a therapeutic option for metabolic conditions where amino acid management is critical, leveraging Bloom Science's expertise in the gut-brain axis and live biotherapeutic products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BL-004.